In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arsia Therapeutics Inc.

www.arsiarx.com

Latest From Arsia Therapeutics Inc.

Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date

Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.

StartUps and SMEs Financing

Start-Up Quarterly Statistics, Q4 2016

A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.

StartUps and SMEs Financing

Deals Shaping the Medical Industry, December 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.

Deals BioPharmaceutical

Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals

Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arsia Therapeutics Inc.
  • Senior Management
  • Amy Schulman, CEO
    Kevin Love, Dir, BD & Ops
    Charles Westcott, PhD, VP, R&D
  • Contact Info
  • Arsia Therapeutics Inc.
    Phone: (617) 863-3693
    Cambridge, MA
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register